Daniel Alcolea

Dementia risk in Parkinson disease: disentangling the role of MAPT haplotypes.

Expansion mutation in C9ORF72 does not influence plasma progranulin levels in frontotemporal dementia.

Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease.

Characterization of the repeat expansion size in C9orf72 in amyotrophic lateral sclerosis and frontotemporal dementia.

Feasibility of lumbar puncture in the study of cerebrospinal fluid biomarkers for Alzheimer's disease: a multicenter study in Spain.

Plasma phosphorylated TDP-43 levels are elevated in patients with frontotemporal dementia carrying a C9orf72 repeat expansion or a GRN mutation.

Posttranslational nitro-glycative modifications of albumin in Alzheimer's disease: implications in cytotoxicity and amyloid-β peptide aggregation.

Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease.

TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis.

Early Cerebellar Hypometabolism in Patients With Frontotemporal Dementia Carrying the C9orf72 Expansion.

Cerebral amyloid angiopathy-related atraumatic convexal subarachnoid hemorrhage: an ARIA before the tsunami.

Relationship between cortical thickness and cerebrospinal fluid YKL-40 in predementia stages of Alzheimer's disease.

Analysis of the CHCHD10 gene in patients with frontotemporal dementia and amyotrophic lateral sclerosis from Spain.

Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease.

Cerebrospinal Fluid Anti-Amyloid-β Autoantibodies and Amyloid PET in Cerebral Amyloid Angiopathy-Related Inflammation.

Progranulin Protein Levels in Cerebrospinal Fluid in Primary Neurodegenerative Dementias.

CSF microRNA Profiling in Alzheimer's Disease: a Screening and Validation Study.

Feasibility of Lumbar Puncture in the Study of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Subjects with Down Syndrome.

A Common Variant in the MC1R Gene (p.V92M) is associated with Alzheimer's Disease Risk.

Cerebrospinal fluid mitochondrial DNA in the Alzheimer's disease continuum.

Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal-dominant Alzheimer's disease.

Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease.

CSF sAPPβ, YKL-40, and neurofilament light in frontotemporal lobar degeneration.

The pitfalls of biomarker-based classification schemes.

Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.

Cortical microstructural changes along the Alzheimer's disease continuum.

Weight loss in the healthy elderly might be a non-cognitive sign of preclinical Alzheimer's disease.

Cerebral changes and disrupted gray matter cortical networks in asymptomatic older adults at risk for Alzheimer's disease.

Challenges associated with biomarker-based classification systems for Alzheimer's disease.

Decreased CX3CL1 Levels in the Cerebrospinal Fluid of Patients With Alzheimer's Disease.

CSF sAPPβ, YKL-40, and NfL along the ALS-FTD spectrum.

Elevated YKL-40 and low sAPPβ:YKL-40 ratio in antemortem cerebrospinal fluid of patients with pathologically confirmed FTLD.

Impact of CSF storage volume on the analysis of Alzheimer's disease biomarkers on an automated platform.

Cortical microstructure in the behavioural variant of frontotemporal dementia: looking beyond atrophy.

A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity.

The gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk.

Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse.

The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders.

Detection of amyloid beta peptides in body fluids for the diagnosis of alzheimer's disease: Where do we stand?

APP-derived peptides reflect neurodegeneration in frontotemporal dementia.

Atrophy of Basal Forebrain Initiates with Tau Pathology in Individuals at Risk for Alzheimer's Disease.

Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity.

Assessing circular RNAs in Alzheimer's disease and frontotemporal lobar degeneration.

Disease-Specific Changes in Reelin Protein and mRNA in Neurodegenerative Diseases.

Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.

Motor cortex transcriptome reveals microglial key events in amyotrophic lateral sclerosis.

Obesity impacts brain metabolism and structure independently of amyloid and tau pathology in healthy elderly.

Cortical microstructure in the amyotrophic lateral sclerosis-frontotemporal dementia continuum.

Cerebrospinal fluid A beta 1-40 peptides increase in Alzheimer's disease and are highly correlated with phospho-tau in control individuals.

Heterozygous APOE Christchurch in familial Alzheimer's disease without mutations in other Mendelian genes.

Serum neurofilament light chain predicts long-term prognosis in Guillain-Barré syndrome patients.

Biphasic cortical macro- and microstructural changes in autosomal dominant Alzheimer's disease.

Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture.

Sex differences in the behavioral variant of frontotemporal dementia: A new window to executive and behavioral reserve.

Diagnostic Utility of Measuring Cerebral Atrophy in the Behavioral Variant of Frontotemporal Dementia and Association With Clinical Deterioration.

AMYQ: An index to standardize quantitative amyloid load across PET tracers.

Common variants in Alzheimer's disease and risk stratification by polygenic risk scores.

Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias.

Association of Apolipoprotein E ɛ4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome.

Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome.

Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study.

Metabolite Signature of Alzheimer's Disease in Adults with Down Syndrome.

Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer's disease, but not in cerebral amyloid angiopathy.

Correction to: Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer's disease, but not in cerebral amyloid angiopathy.

Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia.

The Aβ1-42/Aβ1-40 ratio in CSF is more strongly associated to tau markers and clinical progression than Aβ1-42 alone.

Hypothalamic pregnenolone mediates recognition memory in the context of metabolic disorders.

Pathophysiological Underpinnings of Extra-Motor Neurodegeneration in Amyotrophic Lateral Sclerosis: New Insights From Biomarker Studies.

Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles.

New insights into the genetic etiology of Alzheimer's disease and related dementias.

Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration.

Importance of cerebrospinal fluid storage conditions for the Alzheimer's disease diagnostics on an automated platform.

Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome.

Establishing In-House Cutoffs of CSF Alzheimer's Disease Biomarkers for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort.

Intermediate and Expanded HTT Alleles and the Risk for α-Synucleinopathies.